←
Multiple Myeloma Hub7,077 posts
Multiple Myeloma Hub avatar✓

Multiple Myeloma Hub ✓

@MM_Hub

Global online platform providing the latest treatment options & medical information on #MultipleMyeloma. Intended for HCPs. linktr.ee/MultipleMyelomaHub

◷ Joined April 2017▧ 4,700 Photos and videos
Multiple Myeloma Hub avatar
Multiple Myeloma Hub@MM_Hub·2h

🎥How are BCMA-directed ADCs currently being used in clinical practice, and what future directions are being evaluated? Fredrik Schjesvold, Hermann Einsele, and Marc Raab discuss treatment positioning, management of belantamab mafodotin-associated ocular toxicities, and ongoing studies into BCMA-directed ADCs. Explore the masterclass series here: bit.ly/4Aqd9qC #myeloma #mmsm #MedEd Intended for healthcare professionals. Independently supported by GSK. Funders are allowed no influence.

Post attachment
Multiple Myeloma Hub avatar
Multiple Myeloma Hub@MM_Hub·Nov 17

A new on-demand webinar from the MMRF and RedMedEd explores on-body administration in myeloma care. The webinar features faculty from Mayo Clinic and is designed for hematology/oncology providers. Register: bit.ly/4zntbk4

Post attachment
Multiple Myeloma Hub avatar
Multiple Myeloma Hub@MM_Hub·Nov 16

🎥 What is on the horizon for antibody–drug conjugates in MM? Marc Raab discusses the evaluation of belantamab mafodotin in earlier treatment settings, investigational ADCs with alternative cytotoxic payloads and antigen targets, and potential applications in relapsed/refractory disease. Watch here: bit.ly/4kOoLiy #MultipleMyeloma #myeloma #mmsm #MedEd @RaabMarc Intended for healthcare professionals. Independently supported by GSK. Funders are allowed no influence.

Post attachment
Multiple Myeloma Hub avatar
Multiple Myeloma Hub@MM_Hub·Nov 13

🎥What are the current clinical considerations and future perspectives for BCMA-directed ADCs in #MultipleMyeloma? In our latest masterclass series, Fredrik Schjesvold, Hermann Einsele, and Marc Raab discuss the clinical use of belantamab mafodotin, management of associated ocular toxicities, and future directions for BCMA-directed ADCs. Explore the masterclass series here: bit.ly/4Aqd9qC #myeloma #mmsm #MedEd Intended for healthcare professionals. Independently supported by GSK. Funders are allowed no influence.

Post attachment
Multiple Myeloma Hub avatar
Multiple Myeloma Hub@MM_Hub·Nov 11

🚨 NEWS 🚨 The @EU_Commission approves a label expansion for melflufen + dexamethasone for the treatment of patients with multiple myeloma who have received ≥2 prior LoT and are refractory to lenalidomide and their most recent therapy. This expansion was based on data from clinical studies, including the phase III OCEAN trial, and real-world practice. Read more: onclive.com/view/melflufen-g… #MultipleMyeloma #myeloma #mmsm #MedEd #MedNews

Post attachment
Multiple Myeloma Hub avatar
Multiple Myeloma Hub@MM_Hub·Nov 5

🎧 In our latest podcast, Fredrik Schjesvold discusses the current positioning of belantamab mafodotin-based combinations in MM, including considerations around ocular toxicity and patient preferences when selecting treatment. Listen here: bit.ly/4eFXuLt #MultipleMyeloma #myeloma #mmsm #MedEd @MyelomaOslo Intended for healthcare professionals. Independently supported by GSK. Funders are allowed no influence.

Post attachment
Multiple Myeloma Hub avatar
Multiple Myeloma Hub@MM_Hub·Nov 4

📢 Stay connected with MM in the Know! From educational resources to the latest information for people affected by multiple myeloma, there are plenty of ways to stay informed. 📬 Sign up to our free monthly newsletter: bit.ly/4jUWgzD Follow us on social media for our latest content and updates. #MultipleMyeloma #myeloma

Post attachment
Multiple Myeloma Hub avatar
Multiple Myeloma Hub@MM_Hub·Nov 3

CONGRESS | #IACH2026 | PRESENTATION Claudio Cerchione discussed bispecific antibodies in late RRMM. Cerchione highlighted clinical trial data for single-agent BCMA- and GPRC5D-targeting bispecific antibodies in heavily pretreated disease, and noted that attention is now turning to combinations, bridging therapy before CAR-T cell therapy, and treatment sequencing. He presented early data for the investigational trispecific antibody ramantamig, showing a 100% response rate (n = 27) at the RP2D in triple-class-exposed patients naïve to T-cell redirection therapies, while noting that long-term and early-relapse data are awaited. He also emphasized the importance of an individualized approach and supportive care. Follow our live feed for more updates: multiplemyelomahub.com/medic… Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @TheIACH @DottorClaudio

Post attachmentPost attachmentPost attachmentPost attachment